Literature DB >> 12457785

Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey.

J G F Cleland1, A Cohen-Solal, J Cosin Aguilar, R Dietz, J Eastaugh, F Follath, N Freemantle, A Gavazzi, W H van Gilst, F D R Hobbs, J Korewicki, H C Madeira, I Preda, K Swedberg, J Widimsky.   

Abstract

BACKGROUND: Heart failure is a prevalent condition that is generally treated in primary care. The aim of this study was to assess how primary-care physicians think that heart failure should be managed, how they implement their knowledge, and whether differences exist in practice between countries.
METHODS: The survey was undertaken in 15 countries that had membership of the European Society of Cardiology (ESC) between Sept 1, 1999, and May 31, 2000. Primary-care physicians' knowledge and perceptions about the management of heart failure were assessed with a perception survey and how a representative sample of patients was managed with an actual practice survey.
FINDINGS: 1363 physicians provided data for 11062 patients, of whom 54% were older than 70 years and 45% were women. 82% of patients had had an echocardiogram but only 51% of these showed left ventricular systolic dysfunction. Ischaemic heart disease, hypertension, diabetes mellitus, atrial fibrillation, and major valve disease were all common. Physicians gave roughly equal priority to improvement of symptoms and prognosis. Most were aware of the benefits of ACE inhibitors and beta blockers. 60% of patients were prescribed ACE inhibitors, 34% beta blockers but only 20% received these drugs in combination. Doses given were about 50% of targets suggested in the ESC guidelines. If systolic dysfunction was documented, ACE inhibitors were more likely and beta blockers less likely to be prescribed than when there was no evidence of systolic dysfunction.
INTERPRETATION: Results from this survey suggest that most patients with heart failure are appropriately investigated, although this finding might be as a result of high rates of hospital admissions. However, treatment seems to be less than optimum, and there are substantial variations in practice between countries. The inconsistencies between physicians' knowledge and the treatment that they deliver suggests that improved organisation of care for heart failure is required.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457785     DOI: 10.1016/s0140-6736(02)11601-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  109 in total

1.  Polypharmacy and comorbidity in heart failure.

Authors:  Frederick A Masoudi; Harlan M Krumholz
Journal:  BMJ       Date:  2003-09-06

2.  Clinical burden and health service challenges of chronic heart failure.

Authors:  F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2010-08       Impact factor: 5.386

3.  A novel locus for autosomal-dominant dilated cardiomyopathy maps to chromosome 7q22.3-31.1.

Authors:  Jost Schönberger; Leif Kühler; Elisabete Martins; Tom H Lindner; Jose Silva-Cardoso; Michael Zimmer
Journal:  Hum Genet       Date:  2005-10-14       Impact factor: 4.132

Review 4.  Gender and heart failure: a population perspective.

Authors:  P A Mehta; M R Cowie
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

5.  Is medication review by pharmacists of any use?

Authors:  Arnold G Zermansky; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis.

Authors:  Clare Davenport; Elaine Yee Lan Cheng; Yip Tung Tony Kwok; Annie Hiu On Lai; Taka Wakabayashi; Chris Hyde; Martin Connock
Journal:  Br J Gen Pract       Date:  2006-01       Impact factor: 5.386

7.  Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance.

Authors:  Andreas Schuchert; Giuseppe Boriani; Christian Wollmann; Mauro Biffi; Martin Kühl; Johannes Sperzel; Sascha Stiller; Gianni Gasparini; Dirk Böcker
Journal:  J Interv Card Electrophysiol       Date:  2005-03       Impact factor: 1.900

8.  Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice.

Authors:  Veselin Mitrovic; Karl-Friedrich Appel; Nicolaos Proskynitopoulos; Seyfettin Dereli; Christian Wilhelm Hamm
Journal:  Clin Res Cardiol       Date:  2009-03-18       Impact factor: 5.460

9.  [Holistic therapy of chronic heart failure].

Authors:  C Feldmann; G Ertl; C E Angermann
Journal:  Internist (Berl)       Date:  2014-06       Impact factor: 0.743

Review 10.  Is heart failure different on the two continents (North America and Europe)?

Authors:  Rachel Hughes-Doichev; Mark E Dunlap
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.